T-DXd With or Without Neratinib for HER2 Positive Breast Cancer With Brain Metastasis

A phase II, open-label, multicenter, randomized controlled trial exploring the efficacy and safety of Trastuzumab Deruxtecan combined with or without Neratinib in HER2-positive breast cancer with brain metastasis

Trial Details

NCT ID
NCT07152782
Phase
PHASE2
Sponsor
Fudan University
Status
RECRUITING
Cancer Type
HER2 Positive Breast Cancer
Interventions
  • Neratinib
  • Trastuzumab Deruxtecan
Locations (sample)
  • Shanghai, China|31.22222,121.45806

Key Eligibility Criteria

  • Participants must meet all of the following inclusion criteria in order to be enrolled in this study:
  • Female, aged 18-70 years old.
  • ECOG score ranges from 0 to 1.
  • Expected survival period is greater than 12 weeks.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find HER2 Positive Breast Cancer Trials on Trialify →